Pathogenese, Diagnose und Klinik der Fuchs-Endotheldystrophie

Wacker, Katrin; Reinhard, Thomas; Maier, Philip

doi:10.1007/s00347-018-0799-5

Cited by 8 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Fuchsʼ dystrophy, progressive endothelial dysfunction with characteristic guttae slowly impairs cellular integrity, the barrier function, and the pump-leak mechanism [21]. As these guttae become confluent, patients start to experience symptoms because of corneal remodelling and chronic stromal oedema, and finally bullous keratopathy in advanced stages of Fuchsʼ dystrophy, because of additional epithelial decompensation [26,27].…”

Section: Causes Of Corneal Oedemamentioning

confidence: 99%

Corneal Oedema: Aetiology, Diagnostic Testing, and Treatment

Zander

Jiang

Reinhard

et al. 2022

Klin Monbl Augenheilkd

View full text Add to dashboard Cite

Corneal oedema results from an underlying pathology, which can be diverse in origin, and may be mechanical, dystrophic, or inflammatory, and affect any layer of the cornea. Diagnostic tools such as Scheimpflug imaging and anterior segment optical coherence tomography have standardised quantification of corneal oedema and have become important aids in clinical practice. Timely diagnosis and treatment are key to preventing irreversible damage to the corneal ultrastructure, such as anterior corneal fibrosis or endothelial cell damage. The oedema usually resolves quickly when the underlying cause has been addressed. Symptomatic treatment using hyperosmolar agents has failed to show any benefits in oedema resolution or improvement in visual acuity compared to placebo. In contrast, rho-associated protein kinase (ROCK) inhibitors offer a promising option for medical treatment in cases of endothelial dysfunction, but their safety and efficacy must be further validated in large scale clinical trials. Until then, endothelial or penetrating keratoplasties remain the mainstay treatment where structural changes to the cornea have occurred.

show abstract

Section: Causes Of Corneal Oedemamentioning

confidence: 99%

Corneal Oedema: Aetiology, Diagnostic Testing, and Treatment

Zander

Jiang

Reinhard

et al. 2022

Klin Monbl Augenheilkd

View full text Add to dashboard Cite

show abstract

“…Nach der Erstbeschreibung der Technik DMEK durch Gerrit Melles im Jahr 2006 ist es inzwischen 10 Jahre her, dass die ersten vorläufigen Ergebnisse nach DMEK bei 10 Patienten mit Fuchs-Endotheldystrophie durch die Gruppe Melles veröffentlicht wurden [2]. Dieses 10-jährige Jubiläum dient als Anlass, über stattgehabte und aktuelle Entwicklungen in der Pathogenese, Diagnostik und Therapie der Fuchs-Endotheldystrophie speziell mittels DMEK zu berichten [3][4][5][6].…”

Section: » Minimalinvasive Verfahren Wie Die Dmek Sind Goldstandard Funclassified

Therapie der Fuchs-Endotheldystrophie mittels DMEK

Cursiefen

Bachmann

2018

Ophthalmologe

View full text Add to dashboard Cite

“…Corneal endothelial diseases such as FED and pseudophakic bullous keratopathy (PBK) are characterized by loss of pump and/or barrier function of the endothelium, resulting in stromal and epithelial edema. The two main complaints of patients with corneal endothelial diseases are impairment of central visual acuity and glare [ 5 , 6 ]. Since its introduction in 2006 by Gerrit Melles [ 7 ], Descemet membrane endothelial keratoplasty (DMEK) has become the gold standard therapy for corneal endothelial diseases [ 8 – 10 ].…”

Section: Introductionmentioning

confidence: 99%

Descemet membrane endothelial keratoplasty (DMEK) improves vision-related quality of life

Gellert

Unterlauft

Rehák

et al. 2022

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Purpose To evaluate vision-related quality of life (VRQL) before and after Descemet membrane endothelial keratoplasty (DMEK). Methods The study was conducted in patients with Fuchs endothelial dystrophy or pseudophakic bullous keratopathy undergoing DMEK alone or in combination with cataract surgery (triple-DMEK) between August 2019 and March 2020 at the University of Leipzig Medical Center. Best-corrected visual acuity (BCVA) was measured. Visual acuity factor (VAF) and glare factor (GF) scores were calculated using the Visual Function and Corneal Health Status Instrument questionnaire answered by patients before surgery and 6 months thereafter. Subgroup analyses were performed for DMEK versus triple-DMEK, and for first versus second eyes, in addition to correlation analyses of scores with preoperative BCVA. Results Forty-six patients were included in this analysis. VAF score improved from 0.68 ± 0.54 to 0.02 ± 0.57 (P < 0.0001) and GF score improved from 0.53 ± 0.43 to -0.11 ± 0.39 (P < 0.0001) during follow-up. Both scores improved without significant differences after surgery in the first and in the fellow eye (P < 0.0001) and after DMEK and triple-DMEK (P < 0.0001). The improvement of scores did not correlate with preoperative BCVA (r = 0.06, P = 0.68 for VAF; r = -0.09, P = 0.54 for GF). Conclusion VRQL improves similarly after DMEK and triple-DMEK and between first and second operated eye. The extent of improvement is independent of the preoperative BCVA. The results of this study can be useful when planning DMEK by enabling a prediction of anticipated VRQL gain.

show abstract

Pathogenese, Diagnose und Klinik der Fuchs-Endotheldystrophie

Cited by 8 publications

References 41 publications

Corneal Oedema: Aetiology, Diagnostic Testing, and Treatment

Corneal Oedema: Aetiology, Diagnostic Testing, and Treatment

Therapie der Fuchs-Endotheldystrophie mittels DMEK

Descemet membrane endothelial keratoplasty (DMEK) improves vision-related quality of life

Contact Info

Product

Resources

About